TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats (full – 2011)http://jpet.aspetjournals.org/content/339/1/228.long
Takeda moves potential first-in-class diabetes drug into phase III (news – 2011) http://www.pharmafile.com/news/16698...-875-phase-iii
A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22669289
Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent (abst – 2012)http://www.ncbi.nlm.nih.gov/pubmed/22490067
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial (abst – 2012)http://www.ncbi.nlm.nih.gov/pubmed/22374408
Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes (full – 2013)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920793/
A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1 (full – 2013)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794927/
Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600727/
Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554318/
TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23848179
Fasiglifam as a new potential treatment option for patients with type 2 diabetes (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24195772
High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875 (abst – 2014)http://www.ncbi.nlm.nih.gov/pubmed/25043059
Optimization of GPR40 Agonists for Type 2 Diabetes (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24900872
Physiology and therapeutics of the free fatty acid receptor GPR40 (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24373235
G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24234912
Docosahexaenoic acid, G protein-coupled receptors, and melanoma: is G protein-coupled receptor 40 a potential therapeutic target? (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24576779
Takeda moves potential first-in-class diabetes drug into phase III (news – 2011) http://www.pharmafile.com/news/16698...-875-phase-iii
A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes (abst – 2012) http://www.ncbi.nlm.nih.gov/pubmed/22669289
Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent (abst – 2012)http://www.ncbi.nlm.nih.gov/pubmed/22490067
TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial (abst – 2012)http://www.ncbi.nlm.nih.gov/pubmed/22374408
Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes (full – 2013)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920793/
A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1 (full – 2013)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3794927/
Pharmacometric Approaches to Guide Dose Selection of the Novel GPR40 Agonist TAK-875 in Subjects With Type 2 Diabetes Mellitus (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3600727/
Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes (full – 2013) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554318/
TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/23848179
Fasiglifam as a new potential treatment option for patients with type 2 diabetes (abst – 2013) http://www.ncbi.nlm.nih.gov/pubmed/24195772
High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875 (abst – 2014)http://www.ncbi.nlm.nih.gov/pubmed/25043059
Optimization of GPR40 Agonists for Type 2 Diabetes (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24900872
Physiology and therapeutics of the free fatty acid receptor GPR40 (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24373235
G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24234912
Docosahexaenoic acid, G protein-coupled receptors, and melanoma: is G protein-coupled receptor 40 a potential therapeutic target? (abst – 2014) http://www.ncbi.nlm.nih.gov/pubmed/24576779